Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the workforce modelling used as the basis for the 10 Year Workforce Plan will be independent; and whether the results of that modelling will be independently assessed and tested.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to establish a centralised dataset on localised ADHD assessment waiting times.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government has recognised that, nationally, demand for assessments for attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.
For the first time, NHS England published management information on ADHD assessment waiting times at a national level on 29 May 2025 as part of its ADHD data improvement plan. Data is now released each quarter with the latest release in August 2025.
Data on ADHD waiting times at an integrated care board (ICB) level is not currently held centrally. NHS England has released technical guidance to ICBs to improve the recording of ADHD data, with a view to improving data quality and publishing more localised data. NHS England intends to publish data at an ICB level in 2026/27.
My Rt Hon. Friend, the Secretary of State for Health and Social Care, announced on 4 December the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD, and Autism. This independent review will inform our approach to enabling people with ADHD to have the right support in place to enable them to live well in their communities.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, if he will make an estimate of the number of people with Parkinson's in the Employment and Support Allowance Support Group.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
As of May 2025, there were 2,000 claimants in the Employment and Support Allowance Support Group with the main disabling condition 'Parkinson’s disease or syndrome’. In the same month, there were 300 claimants in the Employment and Support Allowance Support Group with the main disabling condition ‘Parkinsonism’.
Data is based on primary medical condition as recorded on the ESA computer systems. Claimants may have multiple disabling conditions on which their entitlement is based but only the primary condition is available for statistical purposes and shown in these statistics.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he has made an assessment on the potential impact of vape flavour restrictions in (a) Canada, (b) Australia and (c) Netherlands on smoking cessation in the context of the proposed regulation of vape flavours in the United Kingdom.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The youth vaping call for evidence, published in 2023, demonstrated that vape flavours are one of the main reasons that vapes appeal to children. However, we recognise that vape flavours can also be a consideration for adult smokers seeking to quit smoking.
That is why it is important we strike the balance between restricting vape flavours to reduce their appeal to young people, whilst ensuring vapes remain available for adult smokers as a smoking cessation tool.
The Tobacco and Vapes Bill includes regulation making powers to limit vape flavours, to reduce the appeal to children. Before laying any regulations in Parliament, we will undertake a full public consultation to ensure we get this balance right and consider the views of a range of stakeholders. We will publish thorough impact assessments to accompany any future regulations, including future flavour restrictions. These assessments will consider the international evidence available.
In October 2025, we launched a call for evidence to gather information on flavours and substances in vaping, nicotine, and tobacco products, aiming to better understand the role and risks of flavourings and ingredients. The call for evidence also seeks to identify where efforts to control flavours have been effective or not.
Adult smokers will still be able to access vapes as well as alternative methods to support them to stop smoking. Vapes are commonly used alongside behavioural support within local Stop Smoking Services.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of scientific evidence on vape flavours as a smoking cessation aid.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The youth vaping call for evidence, published in 2023, demonstrated that vape flavours are one of the main reasons that vapes appeal to children. However, we recognise that vape flavours can also be a consideration for adult smokers seeking to quit smoking.
That is why it is important we strike the balance between restricting vape flavours to reduce their appeal to young people, whilst ensuring vapes remain available for adult smokers as a smoking cessation tool.
The Tobacco and Vapes Bill includes regulation making powers to limit vape flavours, to reduce the appeal to children. Before laying any regulations in Parliament, we will undertake a full public consultation to ensure we get this balance right and consider the views of a range of stakeholders. We will publish thorough impact assessments to accompany any future regulations, including future flavour restrictions. These assessments will consider the international evidence available.
In October 2025, we launched a call for evidence to gather information on flavours and substances in vaping, nicotine, and tobacco products, aiming to better understand the role and risks of flavourings and ingredients. The call for evidence also seeks to identify where efforts to control flavours have been effective or not.
Adult smokers will still be able to access vapes as well as alternative methods to support them to stop smoking. Vapes are commonly used alongside behavioural support within local Stop Smoking Services.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of flavoured vapes on tobacco smoking cessation.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The youth vaping call for evidence, published in 2023, demonstrated that vape flavours are one of the main reasons that vapes appeal to children. However, we recognise that vape flavours can also be a consideration for adult smokers seeking to quit smoking.
That is why it is important we strike the balance between restricting vape flavours to reduce their appeal to young people, whilst ensuring vapes remain available for adult smokers as a smoking cessation tool.
The Tobacco and Vapes Bill includes regulation making powers to limit vape flavours, to reduce the appeal to children. Before laying any regulations in Parliament, we will undertake a full public consultation to ensure we get this balance right and consider the views of a range of stakeholders. We will publish thorough impact assessments to accompany any future regulations, including future flavour restrictions. These assessments will consider the international evidence available.
In October 2025, we launched a call for evidence to gather information on flavours and substances in vaping, nicotine, and tobacco products, aiming to better understand the role and risks of flavourings and ingredients. The call for evidence also seeks to identify where efforts to control flavours have been effective or not.
Adult smokers will still be able to access vapes as well as alternative methods to support them to stop smoking. Vapes are commonly used alongside behavioural support within local Stop Smoking Services.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve accessibility to (a) education and (b) healthcare for people with progressive neurological conditions such as Friedreich’s Ataxia.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of those living with rare diseases, such as Friedreich’s ataxia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community, and these include: getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. In February we published the fourth England action plan reporting on progress.
NHS England has revised the national service specification for specialised neurology, which now includes an annex providing greater clarity for neurology sub-specialties. This includes the categories of both movement disorders and neurogenetics, into which Friedreich’s ataxia falls. Every specialised National Health Service neurology centre could and should see patients with Friedreich’s ataxia.
The NHS England Genomics Education Programme has also developed a range of educational resources for healthcare professionals. This includes a Knowledge Hub page on Friedreich ataxia, including information on presentation, diagnosis, management, and links for clinicians to further resources, which is available at the following link:
https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/friedreich-ataxia/
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 September 2025 to Question 70441 on Health Services: Disadvantaged, what his Department's planned timescale is for the publication of an (a) impact statement and (b) equalities impact assessment for the 10-Year Health Plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We expect these documents to be published shortly.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to introduce interim access to omaveloxolone for Friedreich’s Ataxia patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether new, licensed medicines represent a clinically and cost-effective use of NHS resources.
NICE is unable to make a recommendation about the use in the NHS of omaveloxolone for treating Friedreich's ataxia in people aged 16 years old and over. This is because the company, Biogen, withdrew its evidence submission. NICE will review its decision if the company decides to make a new submission. Further information can be found at the following link:
www.nice.org.uk/guidance/indevelopment/gid-ta11431
NHS England does not fund medicines where the company has not engaged with NICE. This is to avoid a potential pathway for circumventing the NICE appraisal process.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, what steps he is taking to support (a) YMCA England & Wales and (b) other organisations to build additional move-on accommodation for people leaving supported housing.
Answered by Alison McGovern - Minister of State (Housing, Communities and Local Government)
We have invested over £1 billion in homelessness and rough sleeping services this year, which can be used flexibly to address a range of local needs, including support for young people. The Spending Review protects this record level of investment to tackle homelessness and rough sleeping for the next three years.
For young people ready to live independently, we are delivering the biggest increase in social and affordable housebuilding in a generation, backed by the £39 billion Social and Affordable Homes Programme. We are also reforming the private rented sector to give more security to tenants, bringing an end to rental bidding, outlawing discrimination against prospective tenants with children or those who receive social security benefits; and preventing landlords from demanding large amounts of rent in advance.